Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Jul 06, 2014 10:21am
280 Views
Post# 22719154

July 3 press release

July 3 press releaseI just re-read the July 3rd press release. I get the impression that Don must feel very strongly that RVX is going to be making money soon because of the commitments to Eastern in terms of annual interest commitments and loss of patents to Eastern.

I also get the impression that Eastern/KD must feel that the RVX patents are worth a huge amount of money (along with tax losses).

As I understand it Don/RVX has until Aug 28, 2017 to pay out whatever they owe on the Citi loan and this, to me, means RVX had better have positive cash flow or some sort of purchase like a CVR long before 2017 or he will lose it all.

I guess Don and the board had no choice but to get the extra $30,000,000 OR they could have walked away from RVX and let Eastern have it. However, I'm sure NGN would have fought this or found a  solution.

Once again this re-inforces the extremely high level of belief at RVX, NGN and Eastern that rvx-208 works and that the probability of success in the ph2c trial is extremely high and that there are many applications for rvx-208 in treating many diseases beyond cardio-vascular diseases.

When I first started posting here a few month back I had my doubts about Don's ability to move this ahead. WELL IT FEELS GREAT TO HAVE BEEN PROVEN WRONG. I think things are going to move forward quickly...at least as fast as science permits IMO.

My guess is that we'll hear more posiitive information soon.

Cheers
Toinv
Bullboard Posts